Literature DB >> 4092795

Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo.

C Betterle, A Caretto, A De Zio, B Pedini, C Veller-Fornasa, A Cecchetto, F Accordi, A Peserico.   

Abstract

The frequency of autoimmune disorders was determined in 373 vitiligo patients and in controls matched for sex, age and race. Vitiligo patients had an increased frequency of clinical autoimmune diseases of thyroid (7.5%), stomach (0.8%), parathyroid (1%), adrenal gland (1.3%). Vitiligo patients, without clinical signs of overt autoimmune diseases, also had a statistically significant increase in the frequency of gastric parietal cell (p less than 0.001), thyroid microsomal (p less than 0.05) and adrenal autoantibodies (p less than 0.05). This increased incidence of autoimmune manifestations was correlated with the duration of vitiligo. Furthermore in 94% of the patients with parietal cell autoantibodies a gastric biopsy showed atrophic gastritis. In addition, in 48% of the patients with thyroid microsomal autoantibodies and in 2 out of 6 patients with adrenal autoantibodies without overt diseases at the beginning of the study, the functional investigation of the target organs during the follow-up allowed the detection of the presence or that of the subsequent development of clinical or subclinical dysfunction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4092795     DOI: 10.1159/000249466

Source DB:  PubMed          Journal:  Dermatologica        ISSN: 0011-9075


  12 in total

1.  Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.

Authors:  P Agretti; G De Marco; D Sansone; C Betterle; G Coco; A Dimida; E Ferrarini; A Pinchera; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2010-03-22       Impact factor: 4.256

2.  Development of pemphigus vulgaris in a patient with vitiligo and Hashimoto's thyroiditis.

Authors:  B Yalçin; E Tamer; G G Toy; P Oztas; N Alli
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

Review 3.  [Vitiligo. Diagnosis, differential diagnosis, and current patient management].

Authors:  A Hartmann
Journal:  Hautarzt       Date:  2009-06       Impact factor: 0.751

4.  Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume?

Authors:  G Zettinig; A Tanew; G Fischer; W Mayr; R Dudczak; M Weissel
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

5.  Vitiligo and autoantibodies of celiac disease.

Authors:  Zabihollah Shahmoradi; Jamshid Najafian; Farahnaz Fatemi Naeini; Farinaz Fahimipour
Journal:  Int J Prev Med       Date:  2013-02

6.  The vitiligo in senegal.

Authors:  S O Niang; Maodo Ndiaye; Fatimata Ly; Moussa Diallo; Sonia Bouksani; Assane Diop; Boubacar Ahy Diatta; Mame Thierno Dieng; Assane Kane
Journal:  ISRN Dermatol       Date:  2012-01-11

7.  Anti-thyroid peroxidase antibody in vitiligo: a prevalence study.

Authors:  R Dash; A Mohapatra; B S Manjunathswamy
Journal:  J Thyroid Res       Date:  2015-01-11

Review 8.  Oxidative stress and immune system in vitiligo and thyroid diseases.

Authors:  Roberta Colucci; Federica Dragoni; Silvia Moretti
Journal:  Oxid Med Cell Longev       Date:  2015-03-09       Impact factor: 6.543

9.  Thyroid dysfunction and thyroid antibodies in Iranian patients with vitiligo.

Authors:  Moradi Sedighe; Ghafarpoor Gholamhossein
Journal:  Indian J Dermatol       Date:  2008-01       Impact factor: 1.494

10.  Anti-thyroid peroxidase antibody and vitiligo: a controlled study.

Authors:  Maryam Daneshpazhooh; Mahtab Mostofizadeh G; Javad Behjati; Maryam Akhyani; Reza Mahmoud Robati
Journal:  BMC Dermatol       Date:  2006-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.